Latest Breaking News On - Syndrome outcome study - Page 1 : comparemela.com

Phase 2 trial data shows safety, tolerability and efficacy of imlifidase in GBS patients

Hansa Biopharma today announced positive high-level data from the 15-HMedIdeS-09 phase 2 trial that demonstrated imlifidase was safe and well tolerated when administered prior to standard of care, including rapid improvement in disease-related efficacy measures.

Shahram attarianHansa biopharmaAchim kaufholdHead of department neuromuscular diseasesInternational coordinating principal investigatorInternational guillain barrChief medical officerNeuromuscular diseasesHopitaux universitaires de marseilleSyndrome outcome studyNervous system

Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 trial in Guillain-Barré Syndrome (GBS)

/PRNewswire/ Hansa Biopharma, "Hansa" (NASDAQ Stockholm: HNSA), today announced positive high-level data from the 15-HMedIdeS-09 phase 2 trial that.

United kingdomKlaus sindahlShahram attarianVan doornAchim kaufholdStephanie kenneyHansa biopharmaDrug administrationInternational coordinating principal investigatorVp global corporate affairsInternational guillain barrEuropean medicines agencyHead of department neuromuscular diseasesChief medical officerNeuromuscular diseasesHopitaux universitaires de marseille

Imlifidase Demonstrated Positive Safety, Tolerability, And Early Efficacy Outcomes In 15-Hmedides-09 Phase 2 Trial In Guillain-Barré Syndrome (GBS)

Imlifidase Demonstrated Positive Safety, Tolerability, And Early Efficacy Outcomes In 15-Hmedides-09 Phase 2 Trial In Guillain-Barré Syndrome (GBS)
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United kingdomHansa biopharmaStephanie kenneyAchim kaufholdShahram attarianKlaus sindahlVan doornHead of department neuromuscular diseasesVp global corporate affairsInternational guillain barreDrug administrationInternational coordinating principal investigatorEuropean medicines agencyChief medical officerNeuromuscular diseasesHopitaux universitaires de marseille

Hansa Biopharma AB: Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 trial in Guillain-Barré Syndrome (GBS)

Hansa Biopharma AB: Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 trial in Guillain-Barré Syndrome (GBS)
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomShahram attarianKlaus sindahlStefan klotterAchim kaufholdPrnewswire hansa biopharmaStephanie kenneyVan doornHansa biopharmaHead of department neuromuscular diseasesInternational guillain barrInternational coordinating principal investigatorDrug administrationVp global corporate affairsEuropean medicines agencyChief medical officer

Hansa Biopharma completes enrollment in phase 2 study of imlifidase in Guillain-Barré Syndrome (GBS)

Hansa Biopharma completes enrollment in phase 2 study of imlifidase in Guillain-Barré Syndrome (GBS)
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United kingdomHansa biopharmaKlaus sindahlStephanie kenneyShahram attarianVp global corporate affairsInternational coordinating principal investigatorDrug administrationInternational guillain barrErasmus medical centreHead of department neuromuscular diseasesNasdaq stockholmSyndrome outcome studyNeuromuscular diseasesHopitaux universitaires de marseilleOrphan drug designation